The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 111-116

  Takiguchi, Soichi ^a   Nishino, Yukiko ^a   Inoue, Kazuko ^a   Ikeda, Miyako ^b   Kataoka, Yasufumi ^b   Matsusue, Kimihiko ^b   Nishiyama, Kenichi ^a   Iguchi, Haruo ^c  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Apoptosis; Bisphosphonate; Intraperitoneal dissemination; Pancreatic cancer; Rho

Indexed keywords

INCADRONIC ACID; LYSOPHOSPHATIDIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER CONTROL; CANCER GROWTH; CARCINOMATOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; INTRAPERITONEAL DISSEMINATION; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; RHO-ASSOCIATED KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861533973     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1757     Document Type: Article

References (27)

1. Kleeff J, Michalski C, Friess H and Buchler MW: Pancreatic cancer: from bench to 5-year survival. Pancreas 33: 111-118, 2006. (Pubitemid 44174558)
2. Ueno H, Kiyosawa K and Kaniwa N: Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer 97: 145-151, 2007. (Pubitemid 47057479)
3. Reni M, Cereda S and Galli L: PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen. Cancer Lett 256: 25-28, 2007. (Pubitemid 47334967)
4. Xu Y, Shen Z, Wiper DW, et al: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280: 719-723, 1998. (Pubitemid 28405297)
5. Baker DL, Morrison P, Miller B, et al: Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 287: 3081-3082, 2002. (Pubitemid 34633980)
6. Yamada T, Sato K, Komachi M, et al: Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 279: 6595-6605, 2004. (Pubitemid 38248796)
7. Mills GB and Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582-591, 2003. (Pubitemid 37328830)
8. Horwitz AR and Parsons JT: Cell migration - movin' on. Science 286: 1102-1103, 1999.
9. Chrzanowska-Wodnicka M and Burridge K: Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol 133: 1403-1415, 1996. (Pubitemid 26192339)
10. Honn KV, Tang DG and Chen YQ: Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 18: 392-415, 1992. (Pubitemid 23190619)
11. Fisher JE, Rogers MJ, Halasy JM, et al: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96: 133-138, 1999. (Pubitemid 29036065)
12. Oxford G and Theodorescu D: Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett 189: 117-128, 2003. (Pubitemid 35461990)
13. Jaffe AB and Hall A: Rho GTPases in transformation and metastasis. Adv Cancer Res 84: 57-80, 2002. (Pubitemid 34188194)
14. Virtanen SS, Vaananen HK, Harkonen PL and Lakkakorpi PT: Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62: 2708-2714, 2002. (Pubitemid 34462756)
15. Tassone P, Tagliaferri P, Viscomi C, et al: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88: 1971-1978, 2003. (Pubitemid 36829676)
16. Sawada K, Morishige K, Tahara M, et al: Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 62: 6015-6020, 2002. (Pubitemid 35244445)
17. Hashimoto K, Morishige K, Sawada K, et al: Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res 65: 540-545, 2005.
18. Green LM, Reade JL and Ware CF: Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 70: 257-268, 1984. (Pubitemid 14111307)
19. Ren XD, Kiosses WB and Schwartz MA: Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J 18: 578-585, 1999. (Pubitemid 29057242)
20. Iwamura T, Katsuki T and Ide K: Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn J Cancer Res 78: 54-62, 1987. (Pubitemid 17037867)
21. Vogel I, Kalthoff H, Henne-Bruns D and Kremer B: Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma. Pancreatology 2: 79-88, 2002. (Pubitemid 34639081)
22. Su D, Yamaguchi K and Tanaka M: The characteristics of disseminated tumor cells in pancreatic cancer: a black box needs to be explored. Pancreatology 5: 316-324, 2005. (Pubitemid 41160267)
23. Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000. (Pubitemid 30175914)
24. Hiraga T, Williams PJ, Mundy GR and Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61: 4418-4424, 2001. (Pubitemid 32685769)
25. Kitagawa Y, Hiraga T, Yura Y and Yoneda T: Suppression by incadronate of invasion and growth of A-375 human melanoma in mandible in nude mice. Oncol Rep 13: 211-216, 2005.
26. Rogers TL and Holen I: Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9: 177, 2011.
27. Iguchi H, Mizumoto K, Shono M, Kono A and Takiguchi S: Pancreatic cancer-derived cultured cells: Genetic alterations and application to an experimental model of pancreatic cancer metastasis. In: Culture of Human Tumor Cells. Pfragner R and Freshney RI (eds.) John Wiley & Sons, Inc., Hoboken, NJ, pp81-96, 2004.